HIGH GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 OR BCL6 REARRANGEMENTS
Clinical trials for HIGH GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 OR BCL6 REARRANGEMENTS explained in plain language.
Never miss a new study
Get alerted when new HIGH GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 OR BCL6 REARRANGEMENTS trials appear
Sign up with your email to follow new studies for HIGH GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 OR BCL6 REARRANGEMENTS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Scientists test new weapon in fight against aggressive blood cancer
Disease control OngoingThis early-stage study is testing if adding a new drug called parsaclisib to a standard chemotherapy regimen (R-CHOP) is safe and more effective for patients with newly diagnosed, high-risk diffuse large B-cell lymphoma. The main goals are to find the safest dose of the new combi…
Matched conditions: HIGH GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 OR BCL6 REARRANGEMENTS
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC
-
New hope for Hard-to-Treat cancers: adding a pill to standard chemo
Disease control OngoingThis study is testing if adding a pill called venetoclax to standard chemotherapy works better than chemotherapy alone for people with aggressive types of B-cell lymphoma. The goal is to better control the cancer and keep it from coming back. About 363 adults with specific, hard-…
Matched conditions: HIGH GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 OR BCL6 REARRANGEMENTS
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 20, 2026 14:48 UTC
-
New pill aims to boost cancer fight for seniors
Disease control TerminatedThis study is for people aged 75 and older who have just been diagnosed with certain aggressive types of lymphoma. It compares the current standard treatment (a combination of drugs called R-miniCHOP) to that same treatment plus a new oral drug called CC-486. The main goals are t…
Matched conditions: HIGH GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 OR BCL6 REARRANGEMENTS
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 10, 2026 12:52 UTC